Infection with Vancomycin-Resistant Staphylococcus aureus Containing the vanA Resistance Gene
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Vancomycin-resistant S. aureus was cultured from the exit site of a temporary dialysis catheter of a patient with diabetes, peripheral vascular disease, and persistent foot ulcers. The organism carried the vanA resistance gene, which may have come from the vancomycin-resistant Enterococcus faecalis that was also isolated from the patient, who had received vancomycin for several weeks.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Increasing rates of oxacillin-resistant S aureus or MRSA isolates in both hospital and community settings and the recovery of clinical S aureus isolates both partially and fully 138,139 resistant to vancomycin have complicated the treatment of S aureus IE.”
In the citing paper
“the recovery of clinical S aureus isolates both partially and fully 138,139 resistant to vancomycin have complicated the treatment of S aureus IE.”
In the citing paper
“and is especially prevalent in North America.6,138,139”
Citations
Cites
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Medical Entomology and Zoology · Cited by 17,248
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
Diagnostic molecular microbiology : principles and applications
Persing, D. H. (1993) · ASM Press eBooks · Cited by 1,311
Emergence of Vancomycin Resistance in Staphylococcus aureus
Smith, T. L., Pearson, M. L., Wilcox, K. R., Cruz, C., Lancaster, M. V., Robinson-Dunn, B., Tenover, F. C., Zervos, M. J., Band, J. D., White, E., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902183400701 · Cited by 1,088
Self-citation(2001) · PsycEXTRA Dataset · doi:10.1037/e548252006-001 · Cited by 1,018
Noble, W. C., Virani, Z., & Cree, R. G. A. (1992) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.1992.tb05089.x · Cited by 627
Arthur, M., Molinas, C., Depardieu, F., & Courvalin, P. (1993) · Journal of Bacteriology · doi:10.1128/jb.175.1.117-127.1993 · Cited by 603
Pulsed-field gel electrophoresis as a replacement for bacteriophage typing of Staphylococcus aureus
Bannerman, T. L., Hancock, G. A., Tenover, F. C., & Miller, J. M. (1995) · Journal of Clinical Microbiology · doi:10.1128/jcm.33.3.551-555.1995 · Cited by 550
Self-citationCharacterization of glycopeptide-resistant enterococci from U.S. hospitals
Clark, N. C., Cooksey, R. C., Hill, B. C., Swenson, J. M., & Tenover, F. C. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.11.2311 · Cited by 395
Self-citationApplication of pulsed-field gel electrophoresis to molecular epidemiology
Maslow, J. N. (1993) · Medical Entomology and Zoology · Cited by 382
Research works printed but not linked: 7
- 1997, MMWR Morb Mortal Wkly Rep, 46, 624
- 2000, MMWR Morb Mortal Wkly Rep, 48, 1165
- 2002, MMWR Morb Mortal Wkly Rep, 51, 565
- Kloos WE, Bannerman TL. Staphylococcus and Micrococcus. In: Murray PR, ed. Manual of clinical microbiology. 7th ed. Washington, D.C.: ASM Press, 1999:264-82.
- 2001, MMWR Morb Mortal Wkly Rep, 50, 1
- 1995, MMWR Morb Mortal Wkly Rep, 44, 1
- 1997, MMWR Morb Mortal Wkly Rep, 46, 626
Cited by
Items 401–500 of 1,000
Hughes, C. S., Longo, E., Phillips‐Jones, M. K., & Hussain, R. (2017) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2017.05.011 · Cited by 42
“…for the inter-and intra-species spreading of resistance genes due to the encoding of resistance genes on mobile genetic elements [29] increased after the fi rst in vitro transfer of type A vancomycin resistance genes from enterococci to staphylococci [32], later con fi rmed in vivo [41 – 43].”
Foxley, M. A., Wright, S. N., Lam, A. K., Friedline, A. W., Strange, S., Xiao, M. T., Moen, E. L., & Rice, C. V. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00285 · Cited by 42
Morar, A., Ban-Cucerzan, A., Herman, V., Tîrziu, E., Sallam, K. I., Abd‐Elghany, S. M., & Imre, K. (2021) · Antibiotics · doi:10.3390/antibiotics10121458 · Cited by 42
Glycopeptide resistance in Staphylococcus aureus: is it a real threat?
Gemmell, C. G. (2004) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-004-0307-5 · Cited by 47
Diederen, B. M. W., van Duijn, I., Willemse, P., & Kluytmans, J. A. J. W. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00526-06 · Cited by 46
“aureus in the United States (4) caused widespread alarm among physicians since it was feared that we are entering an era of untreatable S.”
BackgroundVaudaux, P. E., Gjinovci, A., Bento, M., Li, D., Schrenzel, J., & Lew, D. P. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3789-3793.2005 · Cited by 44
“This problem has been compounded recently by the emergence of clinical isolates exhibiting intermediate (19–21, 24, 28, 29, 31, 39, 40, 46) or high (5, 11, 47) levels of resistance to glycopeptides, engendering the risk of virtually untreatable infections.”
BackgroundAntioxidant and Antipathogenic Activities of Citrus Peel Oils
Khan, M. M., Iqbal, M., Hanif, M. A., Mahmood, M. S., Naqvi, S. A., Shahid, M., & Jaskani, M. J. (2012) · Journal of Essential Oil Bearing Plants · doi:10.1080/0972060x.2012.10662601 · Cited by 48
Wong, T., Wu, E.-C., Ko, W., Lee, C., Hor, L., & Huang, I. (2017) · Dermatologica Sinica · doi:10.1016/j.dsi.2017.08.003 · Cited by 41
Using genomics to understand meticillin- and vancomycin-resistant Staphylococcus aureus infections
Giulieri, S. G., Tong, S. Y. C., & Williamson, D. A. (2020) · Microbial Genomics · doi:10.1099/mgen.0.000324 · Cited by 45
“It was first described in 2002 in a patient with endstage renal failure and diabetic foot infection [106].”
BackgroundElward, A. M., McAndrews, J. M., & Young, V. L. (2009) · Aesthetic Surgery Journal · doi:10.1016/j.asj.2009.01.010 · Cited by 45
Barbosa, D. A., Lima, L., Silbert, S., Sader, H. S., Cendoroglo, M. N., Draibe, S. A., Camargo, L. F. A., Vianna, L. A. C., Belasco, A. G. S., & Sesso, R. (2004) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.04.038 · Cited by 41
Sinsimer, D., Leekha, S., Park, S., Marras, S. A. E., Koreen, L., Willey, B. M., Naidich, S., Musser, K. A., & Kreiswirth, B. N. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.9.4585-4591.2005 · Cited by 41
“Staphylococcus aureus constitutes a major public health threat, as it is the leading nosocomially acquired pathogen in the United States (2, 3).”
Backgroundvon Eiff, C., Kokai‐Kun, J. F., Becker, K., & Peters, G. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.11.3613-3615.2003 · Cited by 41
“aureus (VISA) (15) and, more recently, vancomycin-resistant (2, 3) strains.”
Suzuki, T., Swoboda, J. G., Campbell, J., Walker, S., & Gilmore, M. S. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00879-10 · Cited by 41
“aureus recently acquired resistance to vancomycin, a drug of last resort (6, 32, 34).”
BackgroundMethicillin-resistant Staphylococcus aureus: novel treatment approach breakthroughs
Maddiboyina, B., Roy, H., Ramaiah, M., Sarvesh, C. N., Kosuru, S. H., Nakkala, R. K., & Nayak, B. S. (2023) · Bulletin of the National Research Centre/Bulletin of the National Research Center · doi:10.1186/s42269-023-01072-3 · Cited by 46
Staphylococcus aureus Infections: New Challenges from an Old Pathogen
Kanafani, Z. A., & Fowler, V. G. (2006) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1157/13086552 · Cited by 56
Linezolid in the Treatment of Implant-related Chronic Osteomyelitis
Vercillo, M. T., Patzakis, M. J., Holtom, P. D., & Zalavras, C. G. (2007) · Clinical Orthopaedics and Related Research · doi:10.1097/blo.0b013e3180986d60 · Cited by 40
Heyman, H. M., Hussein, A. A., Meyer, J. J. M., & Lall, N. (2009) · Pharmaceutical Biology · doi:10.1080/13880200802434096 · Cited by 40
“Keywords: Melianthus major; methicillin-resistant Staphylococcus aureus; flavonoid http://www.informapharmascience.com/phb caused by the bacteria acquiring genes that produce the enzyme -lactamase that inactivates antibiotics (Chang et al., 2003).”
BackgroundMcCollum, M., Sorensen, S. V., & Liu, L. Z. (2007) · Clinical Therapeutics · doi:10.1016/s0149-2918(07)80085-3 · Cited by 40
The Epidemiology of Staphylococcus Infections
Tenover, F. C., & Gorwitz, R. J. (2014) · ASM Press eBooks · doi:10.1128/9781555816513.ch43 · Cited by 40
Self-citationQureshi, N. K., Yin, S., & Boyle‐Vavra, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085873 · Cited by 44
“VRS1 First clinical VRSA isolate from Michigan (Clonal cluster 5) NARSA [8]”
BackgroundNelson, M. U., Bizzarro, M. J., Baltimore, R. S., Dembry, L. M., & Gallagher, P. G. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.00470-15 · Cited by 43
Chusri, S., & Voravuthikunchai, S. P. (2008) · Journal of Applied Microbiology · doi:10.1111/j.1365-2672.2008.03979.x · Cited by 39
“In 2002, vancomycin-resistant Staph. aureus (VRSA) strains emerged in the United States (Centers for Disease Control and Prevention 2002; Chang et al. 2003), followed by reports of these isolates from other parts of the world (Biedenbach et al. 2007; Emaneini et al. 2007).”
BackgroundNamiecińska, E., Sobiesiak, M., Małecka, M., Guga, P., Różalska, B., & Budzisz, E. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180228164656 · Cited by 44
Electronic reporting of infections associated with hemodialysis.
Rm, K., Ji, T., & Andrus, M. (2005) · PubMed · Cited by 39
Carriers and Antigens: New Developments in Glycoconjugate Vaccines
van der Put, R. M. F., Metz, B., & Pieters, R. J. (2023) · Vaccines · doi:10.3390/vaccines11020219 · Cited by 40
Array synthesis of novel lipodepsipeptide
Siedlecki, J. M., Hill, J., Parr, I. B., Xiang, Y., Morytko, M. J., Zhang, Y., Silverman, J. A., Controneo, N., Laganas, V. A., Li, T., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.07.025 · Cited by 38
Antimicrobial resistance among Gram-positive pathogens in Saudi Arabia
Yezli, S., Shibl, A. M., Livermore, D. M., & Memish, Z. A. (2012) · Journal of Chemotherapy · doi:10.1179/1973947812y.0000000010 · Cited by 38
Havaei, S. A., Azimian, A., Fazeli, H., Naderi, M., Ghazvini, K., Samiee, S. M., Masoumi, Z. T., & Akbari, M. (2012) · ISRN Microbiology · doi:10.5402/2012/215275 · Cited by 47
Short, B. R. D., Vargas, M. A., Thomas, J. C., O’Hanlon, S. J., & Enright, M. C. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki428 · Cited by 42
“This example has been repeated for various antibiotics and now the emergence ofMRSA strains with decreased susceptibility to the antibiotic of last resort, vancomycin, has been reported.(5) The prevalence of antibiotic-resistant S.”
BackgroundInfections of Diabetic Foot Ulcers With Methicillin-Resistant Staphylococcus aureus
Cervantes-García, E., García-González, R., Reséndiz‐Albor, A. A., & Salazar-Schettino, P. M. (2015) · The International Journal of Lower Extremity Wounds · doi:10.1177/1534734614564053 · Cited by 38
“Also, there are reports recognizing new strains of MRSA in diabetic foot ulcers that are also resistant to vancomycin (VA).(13,14) Furthermore, there has been an increase in the incidence of Gram-negative bacteria that produce extended-spectrum β-lactamase, such as Enterobacteriaceae,(15,16) thus becoming another mena…”
BackgroundLaPlante, K. L., & Rybak, M. J. (2004) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2004.06.014 · Cited by 43
Wall teichoic acid protects Staphylococcus aureus from inhibition by Congo red and other dyes
Suzuki, T., Campbell, J., Kim, Y., Swoboda, J. G., Mylonakis, E., Walker, S., & Gilmore, M. S. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks184 · Cited by 36
Genomic Analysis of the Emergence of Vancomycin-Resistant Staphylococcus aureus
Kobayashi, S. D., Musser, J. M., & DeLeo, F. R. (2012) · mBio · doi:10.1128/mbio.00170-12 · Cited by 41
“to have existed in the early 1960s (6), it may seem surprising that VRSA was first isolated in 2002 (14).”
BackgroundEnterococcus Species, Streptococcus gallolyticus Group, and Leuconostoc Species
Arias, C. A., & Murray, B. E. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00202-2 · Cited by 41
Advances and Prospects in Vaccine Development against Enterococci
Kalfopoulou, E., & Hüebner, J. (2020) · Cells · doi:10.3390/cells9112397 · Cited by 40
“Resistance transfer from enterococci to other Gram-positive bacteria, like staphylococci, has also been reported in vitro, and indications for an in vivo exchange exist as well [9,38].”
BackgroundPrevalence of vancomycin-resistant Enterococcus fecal colonization among kidney transplant patients
Freitas, M. C. S., Pacheco‐Silva, Á., Barbosa, D. A., Silbert, S., Sader, H. S., Sesso, R., & Camargo, L. F. A. (2006) · BMC Infectious Diseases · doi:10.1186/1471-2334-6-133 · Cited by 37
Kiechle, F. L., Zhang, X., & Holland-Staley, C. A. (2004) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2004-128-1337-toeaii · Cited by 43
Current and novel antibiotics against resistant Gram-positive bacteria
Pérez, F., Salata, R. A., & Bonomo, R. A. (2008) · Infection and Drug Resistance · doi:10.2147/idr.s3545 · Cited by 40
“Analysis of the index case of VRSA from Detroit, Michigan in 2002 identifi ed the transfer of vanA , a vancomycin resistance determinant linked to Tn 1546 , from E . faecalis to S . aureus , a fi nding replicated in the subsequent six isolates (Chang et al 2003).”
Methicillin-Resistant Staphylococcus aureus
Klevens, R. M., Gorwitz, R. J., & Collins, A. S. (2008) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2008.0044 · Cited by 43
Srinivasan, S., Sheela, D., Shashikala, S., Mathew, R., Bazroy, J., & Kanungo, R. (2006) · Indian Journal of Medical Microbiology · doi:10.1016/s0255-0857(21)02347-1 · Cited by 36
Banerjee, T., & Anupurba, S. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.06208-11 · Cited by 44
“Michigan who had extensive exposure to vancomycin (4).”
BackgroundAntimicrobial Resistance Gene Delivery in Animal Feeds
Lu, K., Asano, R., & DAVIES, J. E. (2004) · Emerging infectious diseases · doi:10.3201/eid1004.030506 · Cited by 36
“We suggest that the use of crude avoparcin preparations in animal feeds from 1975 to 1996 was the origin of the vanHAX cluster in the genesis of VRE (and possibly that found in VRSA) (22,23).”
BackgroundGu, L., Cao, B., Liu, Y., Guo, P., Song, S., Li, R., Dai, H., & Wang, C. (2008) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2008.08.018 · Cited by 36
“Furthermore, vanA-resistant gene can be horizontally transferred from enterococci to a variety of Gram-positive microorganism including Staphylococcus aureus by plasmids, contributing to the emergence of vancomycin-resistant S. aureus (Chang et al., 2003).”
BackgroundKumar, P., Kandi, S. K., Manohar, S., Mukhopadhyay, K., & Rawat, D. S. (2019) · ACS Omega · doi:10.1021/acsomega.8b02625 · Cited by 41
Epidemiology and mechanisms of glycopeptide resistance in enterococci
Zirakzadeh, A. A., & Patel, R. (2005) · Current Opinion in Infectious Diseases · doi:10.1097/01.qco.0000186849.54040.2a · Cited by 36
Goff, D. A., & Dowzicky, M. J. (2007) · Journal of Medical Microbiology · doi:10.1099/jmm.0.46710-0 · Cited by 36
“, 2005; Peeters & Sarria, 2005) and vancomycin (Bozdogan et al., 2003; Chang et al., 2003) highlight the importance of the development of new agents, such as tigecycline, for the appropriate treatment of infections where highly resistant pathogens are suspected or known.”
BackgroundLê, J., & Lieberman, J. M. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.12.1758 · Cited by 41
“The VRSA isolate contained the vanA gene that confers vancomycin resistance in VRE.73 A second documented VRSA infection was reported from Pennsylvania in September 2002.74 This patient also had chronic foot ulcers, and the VRSA isolate contained the vanA resistance gene.”
BackgroundInfluentialVancomycin-Resistant Staphylococcus aureus: A Perfect but Geographically Limited Storm?
Tenover, F. C. (2008) · Clinical Infectious Diseases · doi:10.1086/527393 · Cited by 36
Self-citationAgostinho, A. M., James, G. A., Wazni, O. M., Citron, M., & Wilkoff, B. L. (2009) · Clinical and Translational Science · doi:10.1111/j.1752-8062.2009.00123.x · Cited by 35
Niederhäusern, S. D., Sabia, C., Messi, P., Guerrieri, E., Manicardi, G., & Bondi, M. (2007) · Current Microbiology · doi:10.1007/s00284-007-0115-0 · Cited by 43
Foot Infections in diabetic patients
Tan, J. S. (2004) · Current Infectious Disease Reports · doi:10.1007/s11908-004-0036-z · Cited by 34
Verdier, I., Reverdy, M. E., Étienne, J., Lina, G., Bes, M., & Vandenesch, F. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.3.1024-1027.2004 · Cited by 40
“aureus strains with high-level glycopeptide resistance (5) but seem to be related to antimicrobial sequestration by nonamidated muropeptides within a thickened cell wall (6, 10).”
BackgroundZhang, B., Lu, D., Wang, D. B. R., Kok, Z. Y., Chan‐Park, M. B. E., & Duan, H. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202407869 · Cited by 34
Popiel, K. Y., & Miller, M. A. (2014) · Infection Control and Hospital Epidemiology · doi:10.1086/676860 · Cited by 34
“Initially, it raised concerns because of the paucity of available and effective antimicrobials against this organism and also because of the fear of transmission of the vancomycin resistance genes to other pathogenic organisms, such as Staphylococcus aureus.(3) There are now several parenteral and oral agents with hig…”
BackgroundA Decade-Long Commitment to Antimicrobial Resistance Surveillance in Portugal
Marinho, C. M., Santos, T., Gonçalves, A., Poeta, P. A. C. Q. D., & Igrejas, G. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01650 · Cited by 41
Leena, S. S., Kaul, G., Akhir, A., Saxena, D., Chopra, S., & Deepthi, A. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106046 · Cited by 34
López‐Alcalde, J., Mazón, M. M., Guevara, M., Conterno, L. D. O., Solà, I., Nunes, S. C., & Bonfill, X. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007087.pub2 · Cited by 38
Hasman, H., Villadsen, A. G., & Aarestrup, F. M. (2005) · Microbial Drug Resistance · doi:10.1089/mdr.2005.11.178 · Cited by 34
“4,8,21 Thus, more attention should be paid to plasmids in epidemiological studies.”
del Río, A., García-de-la-Mària, C., Entenza, J. M., Gasch, O., Armero, Y., Soy, D., Mestres, C. A., Pericàs, J. M., Falces, C., Ninot, S. P. I., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02139-15 · Cited by 40
High Prevalence of VanA-Type Vancomycin-Resistant Enterococci in Austrian Poultry
Eisner, A., Feierl, G., Gorkiewicz, G., Dieber, F., Kessler, H. H., Marth, E., & Köfer, J. (2005) · Applied and Environmental Microbiology · doi:10.1128/aem.71.10.6407-6409.2005 · Cited by 34
“The vanA genotype is the predominant type of resistance reported in Europe; it is characterized by acquired inducible resistance to both vancomycin and teicoplanin and is transferable to other significant pathogens, like methicillin-resistant Staphylococcus aureus, due to its location on conjugative plasmids (10, 26).”
BackgroundVoß, A., Mouton, J. W., van Elzakker, E. P., Hendrix, R., Goessens, W. H. F., Kluytmans, J. A. J. W., Krabbe, P. F. M., de Neeling, A. J., Sloos, J. H., Öztoprak, N., et al. (2007) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/1476-0711-6-9 · Cited by 36
“This perhaps has been compounded by the discovery of the vanA-mediated glycopeptide resistant S. aureus from the US where the glycopeptide minimum inhibitory concentrations are demonstrably higher and testing issues are also present, but less problematic [ 10 ,11].”
Molecular Mechanisms of Antibiotic Resistance in Bacteria
Opal, S. M., & Pop-Vicas, A. E. (2010) · Elsevier eBooks · doi:10.1016/b978-0-443-06839-3.00019-9 · Cited by 40
McCollum, M., Rhew, D. C., & Parodi, S. M. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)90101-9 · Cited by 34
Immunomodulatory effects of recombinant lactoferrin during MRSA infection
Hwang, S.-A., Kruzel, M. L., & Actor, J. K. (2014) · International Immunopharmacology · doi:10.1016/j.intimp.2014.02.029 · Cited by 33
“However, emergence of vancomycin resistance (6), coupled with waning efficacy of vancomycin on strains with high MIC values (7, 8), indicate a need for development of novel treatment options for therapeutic intervention of MRSA infections.”
BackgroundElliott, R. A., Weatherly, H. L. A., Hawkins, N., Cranny, G., Chambers, D., Myers, L., Eastwood, A. J., & Sculpher, M. (2009) · The European Journal of Health Economics · doi:10.1007/s10198-009-0175-0 · Cited by 33
Transferable vancomycin resistance in clade B commensal-type Enterococcus faecium
Lebreton, F., Valentino, M. D., Schaufler, K., Earl, A. M., Cattoir, V., & Gilmore, M. S. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky039 · Cited by 33
The role of endothelial cell biology in endocarditis
Chorianopoulos, E., Bea, F., Katus, H. A., & Frey, N. (2008) · Cell and Tissue Research · doi:10.1007/s00441-008-0687-4 · Cited by 35
“…topic, stating that the three major pathogens of infective endocarditis (streptococci, staphylococci, and enterococci) exhibit increasing multidrug resistance (Gordon et al. 2002; Diekema et al. 2001; Chambers 2001; Salgado et al. 2003; Smith et al. 1999; Chang et al. 2003; Tsakris et al. 2001).”
BackgroundAnderson, J. F., Parrish, T. D., Akhtar, M., Žůrek, L., & Hirt, H. (2008) · Applied and Environmental Microbiology · doi:10.1128/aem.02164-07 · Cited by 33
“aureus in several unrelated instances (1, 4, 34).”
BackgroundYoon, Y. K., Lee, S. E., Lee, J., Kim, H. J., Kim, J., Park, D. W., Sohn, J. W., & Kim, M. J. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr204 · Cited by 33
Ishii, K., Tabuchi, F., Matsuo, M., Tatsuno, K., Sato, T., Okazaki, M., Hamamoto, H., Matsumoto, Y., Kaito, C., Aoyagi, T., et al. (2015) · Scientific Reports · doi:10.1038/srep17092 · Cited by 35
In Vitro Antibacterial Activity of DX-619, a Novel Des-Fluoro(6) Quinolone
Fujikawa, K., Chiba, M., Tanaka, M., & Sato, K. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3988.2005 · Cited by 33
Genomics, Transcriptomics, Proteomics, and Numbers
Kiechle, F. L., & Holland-Staley, C. A. (2003) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2003-127-1089-gtpan · Cited by 38
Vimberg, V., Zieglerová, L., Buriánková, K., Branny, P., & Novotna, G. B. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00566 · Cited by 32
“Although the incidence of such an event remains low, apparently due to the high fitness cost of vanHAXmediated resistance in S. aureus (Foucault et al., 2009), VRSA strains may represent progenitors for the generation of vanZTeicarrying mobile genetic elements.”
BackgroundInfluentialOfner-Agostini, M., Johnston, B., Simor, A. E., Embil, J. M., Matlow, A., Mulvey, M. R., Ormiston, D., Conly, J. M., & Program, C. N. I. S. (2008) · Infection Control and Hospital Epidemiology · doi:10.1086/528812 · Cited by 32
“Although VRE is a rather low virulence pathogen, there is concern that vancomycinresistance genes may transfer to Staphylococcus aureus.(1) Surveillance is one component of a strategy to identify and limit the spread of VRE in hospitals.”
BackgroundDeplano, A., Denis, O., Nonhoff, C., Rost, F., Byl, B., Jacobs, F., Vankerckhoven, V., Goossens, H., & Struelens, M. J. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm270 · Cited by 32
“aureus (MRSA) underscores the danger of coexistence of both pathogens in the hospital setting.(26) – 28 As MRSA is already endemic in many European hospitals, prevention of VREF dissemination is a public health priority.”
BackgroundCha, J., Vakulenko, S. B., & Mobashery, S. (2007) · Biochemistry · doi:10.1021/bi7005459 · Cited by 32
Lepak, A. J., Parhi, A. K., Madison, M., Marchillo, K., VanHecker, J., & Andes, D. R. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01464-15 · Cited by 30
Zuo, G., An, J., Han, J., Zhang, Y.-L., Wang, G.-C., Hao, X., & Bian, Z. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13078210 · Cited by 32
“aureus (VRSA) has also been reported [1].”
Do we really need new anti-infective drugs?
Rice, L. B. (2003) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2003.05.001 · Cited by 36
Synthesis, Antibacterial Evaluation, and QSAR of Caffeic Acid Derivatives
de Araújo, M. O., Pessôa, H. L. F., Lira, A. B., Pérez‐Castillo, Y., & de Sousa, D. P. (2019) · Journal of Chemistry · doi:10.1155/2019/3408315 · Cited by 35
“Vancomycin is an alternative; however, there are already case reports of intermediate [11] and full resistance to the drug [12].”
BackgroundMechanism of Intrinsic Resistance to Vancomycin in Clostridium innocuum NCIB 10674
David, V., Bozdoğan, B., Mainardi, J., Legrand, R., Gutmann, L., & Leclercq, R. (2004) · Journal of Bacteriology · doi:10.1128/jb.186.11.3415-3422.2004 · Cited by 31
Salzer, W. L. (2005) · Peritoneal Dialysis International · doi:10.1177/089686080502500402 · Cited by 33
“In 2002, the f irst clinical isolate of vancomycinresistant S. aureus (VRSA) was reported ( 11 ).”
BackgroundInVitro Antibacterial Activity of DX-619, a Novel Des-Fluoro(6) Quinolone
Fujikawa, K., Chiba, M., Tanaka, M., & Sato, K. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.7.3040-3045.2005 · Cited by 31
Pankuch, G. A., Lin, G., Hoellman, D. B., Good, C. E., Jacobs, M. R., & Appelbaum, P. C. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.5.1727-1730.2006 · Cited by 31
“aureus (VRSA) strains carrying vanA have been reported in the literature (3, 4, 22), with an additional two strains reported in Michigan (J.”
BackgroundThe Origin, Evolution, and Local and Global Dissemination of Antimicrobial Resistance
Aarestrup, F. M. (2019) · ASM Press eBooks · doi:10.1128/9781555817534.ch20 · Cited by 34
Frey, K. M., Viswanathan, K., Wright, D. L., & Anderson, A. C. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06263-11 · Cited by 33
“Although vancomycin is often used to treat hospitalacquired infections, several MRSA strains were identified with vancomycin resistance transferable from Enterococcus (4, 23).”
BackgroundDaptomycin: a new treatment for insidious infections due to gram-positive pathogens
Cottagnoud, P. (2008) · Swiss Medical Weekly · doi:10.4414/smw.2008.12045 · Cited by 35
Infection Control Epidemiology and Clinical Microbiology
Diekema, D. J., & Pfaller, M. A. (2011) · Wiley eBooks · doi:10.1128/9781555816728.ch6 · Cited by 30
Furtado, G. H. C., Martins, S. T., Coutinho, A. P., Wey, S. B., & Medeiros, E. A. (2005) · The Brazilian Journal of Infectious Diseases · doi:10.1590/s1413-86702005000100011 · Cited by 30
Reyes, K., Malik, R., Moore, C. L., Donabedian, S. M., Perri, M. B., Johnson, L., & Zervos, M. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.02381-08 · Cited by 30
Valsesia, G., Medaglia, G., Held, M., Minas, W., & Panke, S. (2006) · Applied and Environmental Microbiology · doi:10.1128/aem.01969-06 · Cited by 30
“Nowadays, about 70% of nosocomial infections in the United States are resistant to at least one antibiotic (35), and in 2002, the first clinical isolate of Staphylococcus aureus with high-level resistance to vancomycin, a drug of last resort, was isolated (8).”
BackgroundViviani, M., SAENE, H. K. F. V., Dezzoni, R., Silvestri, L., Lenarda, R. D., Berlot, G., & Gullo, A. (2005) · Anaesthesia and Intensive Care · doi:10.1177/0310057x0503300312 · Cited by 30
Antimicrobials from endophytes as novel therapeutics to counter drug-resistant pathogens
Tiwari, P., Thakkar, S., & Dufossé, L. (2024) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2024.2342979 · Cited by 33
“This feature increases the relevance and threat of this microorganism as a pathogen [161].”
Phan, A., Mijar, S., Harvey, C. M., & Biswas, D. (2025) · Microorganisms · doi:10.3390/microorganisms13081732 · Cited by 35
“However, around the time vancomycin started being used to treat MRSA, vancomycin-resistant Ente-rococci emerged in healthcare facilities, and the first vancomycin-resistant S. aureus strain was isolated in a patient in 2002 [54].”
Jia, K., Qin, X., Bu, X., Zhu, H., Liu, Y., Wang, X., Li, Z., & Dong, Q. (2023) · Current Research in Food Science · doi:10.1016/j.crfs.2023.100669 · Cited by 30
“(Cong et al., 2020; Chang et al., 2003; Pan et al., 2018; Ahosanul et al., 2021).”
Treatment of methicillin-resistant Staphylococcus aureus in Latin America
Luna, C. M., Rodríguez-Noriega, E., Luis Bavestrello, F., & Gotuzzo, E. (2010) · The Brazilian Journal of Infectious Diseases · doi:10.1590/s1413-86702010000800007 · Cited by 37
“aureus can also develop full resistance to vancomycin (VRSA), which occurs through the acquisition of resistance genes (vanA) from vancomycin-resistant enterococci.(38,39) The evolution of resistance to vancomycin has been associated with a polymorphism in the accessory gene regulator (agr), and studies have found a h…”
BackgroundDetection of glycopeptide resistance genes in enterococci by multiplex PCR
Bhatt, P., Sahni, A. K., Praharaj, A. K., Grover, N., Kumar, M., Chaudhari, C., & Khajuria, A. (2014) · Medical Journal Armed Forces India · doi:10.1016/j.mjafi.2014.03.005 · Cited by 29
“Resistance to glycopeptides is disseminating rapidly and has spread to methicillin resistant Staphylococcus aureus.(8) Rapid identification of VRE colonized patient is thus essential for detection of such clinical isolates to prevent the spread of VRE.”
BackgroundSalamaga, B., Prajsnar, T. K., Jareño-Martinez, A., Willemse, J. J., Bewley, M. A., Chau, F., Belkacem, T. B., Meijer, A. H., Dockrell, D. H., Renshaw, S. A., et al. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006526 · Cited by 30
“Vancomycin-Resistant Enterococci (VRE) represent a major problem in clinical settings as they can potentially transfer resistance genes to other pathogens such as Staphylococcus aureus [3, 4].”
BackgroundThe implications of enterococci for the intensive care unit
Chatterjee, I., Iredell, J. R., Woods, M. L., & Lipman, J. (2007) · Critical Care and Resuscitation · doi:10.1016/s1441-2772(23)02008-2 · Cited by 30
Metadata
- Authors
- Chang, S., Sievert, D. M., Hageman, J. C., Boulton, M. L., Tenover, F. C., Downes, F. P., Shah, S., Rudrik, J. T., Pupp, G. R., Brown, W. J., Cardo, D., & Fridkin, S. K.
- Affiliations
- Centers for Disease Control and Prevention (US)
- Michigan Department of Health and Human Services (US)
- Wayne State University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-04-03
- Volume
- 348
- Issue
- 14
- Pages
- 1342-1347
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2068037991
- Semantic Scholar
- f0afb59f819a65ada63076a36807f63502c4437d
- Cited by
- 1,095
- References
- 18
- Citations by year
- 2026: 10 · 2025: 15 · 2024: 24 · 2023: 28 · 2022: 24 · 2021: 35 · 2020: 29 · 2019: 39 · 2018: 28 · 2017: 29 · 2016: 28 · 2015: 55 · 2014: 54 · 2013: 51 · 2012: 65
- FWCI
- 54.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Health Sciences › Medicine › Microbiology (medical) › Infections and bacterial resistance
- Keywords
- vancomycin-resistant Staphylococcus aureus, vanA gene, vancomycin resistance, diabetes mellitus, peripheral vascular disease, foot ulcer, vancomycin-resistant Enterococcus faecalis, antibiotic resistance transfer, catheter-related infection
- MeSH terms
- Adult, Catheterization, Debridement, Female, Renal Dialysis, Humans, Staphylococcal Infections, Staphylococcus aureus, Vancomycin, Contact Tracing, Diabetic Foot, Vancomycin Resistance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.